Lyme Disease Comprehensive Protocol

CDC estimates about 476,000 people are diagnosed and treated for Lyme disease in the US each year. It is caused by the bacterium Borrelia burgdorferi, spread by ticks. About 70 to 80% of infected people get an expanding rash, and many rashes are not the classic bull's-eye. Early Lyme responds well to prompt antibiotics, and that evidence is strong. Later Lyme can affect joints, nerves and the heart. Some people have lasting fatigue, pain or brain fog after treatment. IDSA calls this post-treatment Lyme disease syndrome; ILADS considers persistent infection possible. Randomized trials (including Berende, NEJM 2016) found that longer antibiotic courses did not improve quality of life for persistent symptoms, so the long-term approaches in this protocol rest on weaker evidence. Borrelia can form biofilms and persister forms in lab studies, which is why some clinicians use combinations and biofilm agents. Herbal protocols have lab evidence and many patient reports. Coinfections such as Babesia and Anaplasma need their own treatment. Low-dose naltrexone helps some people with pain. A clinician experienced in Lyme can help weigh these choices with you.